{
    "pmcid": "7744031",
    "qa_pairs": {
        "What is a key advantage of nanobodies over conventional antibodies mentioned in the summary?": [
            "Their small size allows them to access epitopes that are difficult for conventional antibodies to reach.",
            "They have a longer half-life in the bloodstream compared to conventional antibodies.",
            "They are more cost-effective to produce than conventional antibodies.",
            "They have a broader range of target specificity than conventional antibodies."
        ],
        "What is a potential therapeutic application of single-domain antibodies mentioned in the summary?": [
            "Delivery directly to the lungs via nebulization",
            "Intravenous administration for systemic infection",
            "Oral administration for gastrointestinal infections",
            "Topical application for skin infections"
        ],
        "What is the primary target for single-domain antibodies in combating SARS-CoV-2 as described in the summary?": [
            "The receptor-binding domain (RBD) of the Spike protein",
            "The nucleocapsid protein",
            "The membrane protein",
            "The envelope protein"
        ],
        "Which display technologies are used to isolate single-domain antibodies from libraries according to the summary?": [
            "Phage and yeast display technologies",
            "Bacterial and mammalian display technologies",
            "Ribosome and mRNA display technologies",
            "Cell-free and in vivo display technologies"
        ],
        "Which single-domain antibody was identified from a llama and binds to an epitope shared between SARS-CoV-1 and SARS-CoV-2?": [
            "VHH-72",
            "Ty1",
            "Nb20",
            "Nb100"
        ]
    }
}